Roivant Sciences Ltd

F:87S

Roivant Sciences Ltd., founded in 2014 by entrepreneur Vivek Ramaswamy, emerged as a novel entity in the pharmaceutical industry by rethinking the drug development process. At the heart of Roivant’s strategy is its unique model of deploying a family of subsidiaries, each focused on developing a specific therapeutic area, referred to as “Vants.” These subsidiaries operate semi-independently, allowing for a nimble and focused approach to drug development while sharing centralized resources like regulatory expertise and funding strategies from Roivant itself. This decentralized yet coordinated structure aims to sidestep the traditional bottlenecks of large pharmaceutical companies, accelerating the time it takes to bring drugs from development to market. Roivant generates revenue by acquiring underdeveloped or previously shelved drug candidates from other pharmaceutical companies, then developing them through their Vants. Once these drugs have proved their potential through clinical trials, Roivant either licenses them out, partners with other companies for further development and commercialization, or sells a stake in the developed drug or entire Vant. This innovative approach allows them not only to mitigate risks associated with drug development but also to tap into a wide range of therapeutic areas, leveraging modern approaches like digital technology to optimize the drug development pipeline. Through this strategy, Roivant aims to capitalize on the inefficiencies in the pharmaceutical industry, delivering valuable medical solutions while generating substantial economic returns.